Search

Molecular tests for the detection of up to 37 subtypes of the Human Papillomavirus (Papillomavirus or HPV)

The High PapillomaStrip and High+Low PapillomaStrip kits are two molecular tests for professional use, which allow the qualitative detection and genotyping of 19 and 37 subtypes (respectively) of Human Papillomavirus (Papillomavirus or HPV) in DNA samples from cervical smears or biopsies, penile smears and urine.

The High PapillomaStrip and High+Low PapillomaStrip kits are two molecular tests that offer advanced detection and genotyping of Human Papillomavirus (HPV), allowing the identification of up to 37 subtypes in a single test. Both tests are designed to detect specific sequences of the highly conserved E6/E7 regions of the viral DNA, which are directly involved in carcinogenesis. Detection of these regions allows for a more accurate and reliable diagnosis, differentiating high- and low-risk genotypes with high sensitivity.

HPV is the most common sexually transmitted disease (STD) worldwide, with more than 40 genotypes capable of infecting the ano-genital tract. Of these, one third are directly linked to cervical cancer and anal neoplasia. More than 90% of cervical cancer cases are caused by untreated HPV infections, making it the fourth most common cancer in women globally.

According to the WHO, HPV screening is one of the most effective methods for the early detection of pre-cancerous lesions, identifying the presence of the virus before it causes tissue damage. The ability to detect and differentiate high- and low-risk genotypes from the E6/E7 regions makes High PapillomaStrip and High+Low PapillomaStrip essential tools for the prevention and control of HPV-associated cancer.

Reliable

Detection of co-infections

37 subtypes in 1 test

Amplification of E6/E7 regions

Use of genotype-specific primers and probes

Our products for the detection and genotyping of High an Low HPV

Product
Technique
Sample
Promotional Sheet
CE Decl.
Catalogue No.
High+Low PapillomaStrip
Hybridization on Strip
DNA from cervical smears or biopsies, penile smears and urine
3.148.016.53.000
3.148.048.53.000
High PapillomaStrip
3.146.016.53.000
Detection of 19 or 37 HPV subtypes in one test. This allows professionals to obtain more complete information for the diagnosis, as well as monitoring during the infection (they can verify whether or not the subtypes disappear) and after HPV vaccination.
Individual detection of all the subtypes. Non-clustered detection of the subtypes allows the identification of possible co-infections, as it provides more detailed information about the presence of those subtypes.
Use of genotype-specific primers and probes. This increases the specificity of the test and eliminates cross-reactions, making the result obtained more reliable.

Amplification of E6/E7 regions instead of L1. HPV PCR strategies targeting the E6/E7 region may be preferable to L1 due to the following reasons:

  • E6 and E7 are the oncogenic regions of HPV.
  • E6 and E7 exhibit strong sequence conservation even after infection, whereas E2 and L1 can be deleted.
  • The E6/E7 sequence differs between high and low-risk HPV types, thus providing diagnostic discrimination using PCR for testing.
  • E6 and E7 are conserved and stable regions. Those characteristics ensure its detection.

Publications

N.º
Title
Link
Language
C1
Comparison of five automated CE/IVD labeled HPV DNA genotyping test systems
English
C2
Prevalence and genetic distribution of human Papyloma virus in women with cervical intraepithelial neoplasia
English
C3
Incidence of Chlamydia trachomatis infection in high risk human papillomavirus infected young women
English
C4
Preliminary evaluation of the High+Low PapillomaStrip Assay Colli-PeeTM collected UCM preserved urine
English
A1
Human papillonavirus infection in oral fluids of HIV-1-positive men: prevalence and risk factors
English
A2
Current HPV tests
English
A3
Test Kitu Detekci a Genotypizaci HPV – High a Low Papilloma Strip 8 + 8 strips
Polish
A4
Identificación, Incidencia y Distribución de Genotipos del Virus del Papilloma Humano en una muestra de la población costarricense
Spanish
A5
Human papilloma virus genotyping in women with abnormal cytology (Ocena genotypów wirusów brodawczaka ludzkiego u kobiet z nieprawidlowa cytologia)
Polish
A6
Erfaringer med HPV-­testing
Norwegian
A7
In situ FoxP3+ and IL-10 over expression is associated with high grade anal lessions in HIV infected patients
English
A8
Human Papillomavirus Genotyping among Different Cervical Smears in Duhok/Irak
English
A9
Colli-Pee – Performance of a game-changing sampling device for HPV-based cervical cancer screening
English
A10
Human Papillomavirus Genotype Distribution among Cervical Cancer Patients prior to Brazilian National HPV Immunization Program
English
A11
Secretory leukocyte protease inhibitor expression and high-risk HPV infection in anal lesions of HIV positive patients
English
A12
Genetic diversity and bioinformatic analysis in the L1 gene of HPV genotypes 31, 33 and 58 circulating in women with normal cervical cytology
English
A13
Influence of sexually transmitted infections on the cervical cytological abnormalities among Iranian women: A cross-sectional study
English
A14
Prevalence of Human Papillomavirus (HPV) Genotypes among Women During 2015-2020 in Mashhad, Iran
English
A15
Comparison of four different human papillomavirus genotyping methods in cervical samples: Addressing method-specific advantages and limitations
English
A16
HPV and HIV Coinfection in Women from a Southeast Region of Romania—PICOPIV Study
English
A17
Distribution of HPV genotypes in Mashhad, Iran: insights from a 2022-2023 study
English
A18
HPV Genotype Trends in Iran: Necessity for a Reevaluation of Prevention Strategies
English
A19
Associations between genetic HPV 16 diversity and cervical cancer prognosis
English
A20
Detection of Viruses with Oncogenic and Oncomodulatory Potential in Head and Neck Tumors-External Auricle
English
A21
Dynamics of Cervical Lesions After Excisional Treatment in Relation to HPV Genotypes and Cytological Findings
English
A22
HUMAN PAPILLOMA VIRUS (HPV) AS A POTENTIAL CO-FACTOR IN BREAST CANCER - A RETROSPECTIVE CASE-CONTROL STUDY
English
A23
Human Papillomavirus Genotype Distribution in Women with Minor Cervical Cytological Abnormalities
English
A24
High prevalence of HPV-56 and HPV-39 in Sari, Iran: an analysis of genotype distribution
English
A25
Molecular-Epidemiological Study for 19 High and Medium- Risk HPV Types in Bulgarian Patients
English
A26
P-159 Association of acrochordons and colorectal polyps: A pilot study to identify potential genetic or viral etiology
English
A27
Enfermedad de Heck: Caso atípico en un adolescente sano originario de Ecuador
Spanish
T1
Validation of a self-sampling device for the screening of the Human Papilloma Virus (HPV) in the Catalan Population
English
T2
Determinación de genotipos del Virus de Papiloma Humano y análisis con el marcador inmunohistoquímico Ki67 en biopsias con displasia cervical de pacientes del Hospital Dr. Max Peralta de Cartago durante el Año 2013
Spanish

Webinars

"New strategies for cervical cancer prevention".

In this webinar, Dr. Paula Cortiñas, renowed gynecologist, talks about how to prevent cervical cancer and its direct link to HPV infections.

The recorder webinar is available on demand. If you missed it, feel free to request it!

dr-paula-cortiñas-hpv
Contact us for more
information

    Frequently Asked Questions

    The anogenital HPVs are generally divided into two categories: those with a low oncogenic potential risk (Low-Risk Group) and those with a medium-high oncogenic potential risk (Medium-High-Risk Group). The high-risk HPVs are generally associated with high-grade precancerous lesions and invasive cancer (16 and 18 subtypes cause 70% of these lesions), while low-risk HPVs are frequently found in asymptomatic or benign conditions such as genital warts. These differences in the oncogenic potential of HPVs make necessary to identify the type of HPV present in the sample, which will allow much more targeted treatment at an earlier stage of the disease.

    When taking the swab, it is recommended to store it without any transport media. If PBS is added (maybe because other exams are made that require this PBS), then the sample should be stored frozen until the extraction. Otherwise, other microorganisms might grow, increasing DNA quantity and degrading the sample. Before the extraction, the dry swab is then resuspended in 500 µl of PBS in a 1,5 ml tube, mixing with vortex for 1 minute. After that, centrifugue the tube for 2 minutes, at 18.000 g. After discarding the supernatant, add 500 µl of PBS, and resuspend the pellet by vortex. Centrifugue the tube for 2 minutes, at 18.000 g. Discard the supernatant. Resuspend the pellet with 200 µl of PBS, and proceed as indicated in the protocol (20 µl of proteinase K + 20 µl buffer AL, etc). By doing that, interferent material will be eliminated, and the PCR will be “cleaner”.

    Generally, it is not possible to calculate a diagnostic sensitivity and specificity, but rather a concordance of sensitivity and specificity between 2 techniques, as neither is really the Gold Standard. In other words, only how one compares with the other can be said. On the other hand, the techniques compared do not detect exactly the same types. This means that, if one of the types not detected by one of the techniques is present, there will be a discordance. Not because of a false result, but because the test is not set up to detect it.

    Use a dry, sterile cotton swab or brush for sampling. Be sure to take a sufficient amount of sample, but without bleeding from the lesion. Keep the swab in its tube, without using any preservative medium. Store it at 2/8 ºC if it is to be processed in less than a week or at – 20ºC if it is to be processed later.
    No, the presence of lesions is not necessary. The diagnosis can be made before the appearance of lesions.
    Self-collection kits have not been validated, in principle it is advisable that the collection is performed by a professional.

    One possible explanation is that the patient becomes infected and recovers between tests. If its a mild infection and the immune system is strong, the patient may overcome the infection and be re-infected with other types by the next test. There is also the possibility that the patient may have co-infections with several HPV types, but that all of them have a very low viral load. In these cases, it is possible that not all types will be amplified in each test, but that they will be amplified randomly. Since the types are not repeated, this does not seem likely, but cannot be ruled out. Another reason could be that there were contaminations in the different assays. It is unlikely to have occurred in several assays in a different way, but this should always be checked by placing blanks in all assays to ensure the veracity of the results.

    Possibly contamination. Blanks should be tested: if they are correct, then the result is valid. This is not surprising because multiple infection in these cases is common. On the other hand, if the blank test comes back contaminated, then there is contamination. In this case, the reagents should be discarded and the cleaning protocol should be performed. No further samples should be tested until several valid blanks are obtained.